Chapter 15: Myeloproliferative Neoplasms

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to The Deep Dive.

Today we're undertaking a critical exploration into a really

fundamental area of hematology, the myeloproliferative neoplasms or MPNs.

It's a huge topic and it's so important because it's where modern molecular biology just slams right into clinical practice.

MPNs are at their core clonal conditions.

Clonal meaning they come from one single bad cell.

Exactly.

One bone marrow stem cell acquires a genetic change or transformation and that leads to this unregulated proliferation of, well, one or more blood components.

It could be red cells, white cells, or platelets.

And this isn't just happening neatly inside the bone marrow, is it?

No, not at all.

It often spills over.

You start seeing this proliferation in secondary sites like the spleen or the liver, which is where a lot of the clinical problems start.

Okay, so let's unpack this.

For anyone studying this right now, the focus is almost always on what we call the big three.

Classic MPNs, yeah.

First you've got polycythemia vera or PV, too many red cells.

Then essential thrombocythemia, ET, too many platelets.

And finally,

primary myelophyte process, PMF, which is the one characterized by that intense scarring in the bone marrow.

Right.

And our mission today, I think, is to cut through those different clinical pictures and really get at their shared genetic basis.

We'll look at their unique challenges and crucially see how modern diagnostics, specifically molecular testing,

have become the absolute bedrock for everything.

For investigation, for management.

You can't practice hematology today without it.

Understanding how one specific gene mutation translates into a specific disease is, well, it's everything.

I find that conceptual unity just fascinating.

It's almost like they aren't totally separate diseases, but maybe different stops on the same broken railway line.

So let's start there with that shared foundation, the molecular landscape and genetic drivers of MPN.

That's the perfect place to start.

What's immediately striking is just how closely related PV, ET, and PMF really are.

They all start from a somatic mutation, one acquired mutation in a single pluripotential stem cell.

And because of that, you see a lot of overlap.

A huge amount.

Yeah.

The source material is very clear that transitional forms are common.

This isn't a static diagnosis you get and just sit with.

For example, a patient might begin with what looks like classic essential thrombocythemia.

And then years later, years later, that disease evolves into what we call post -ET myelofibrosis.

And likewise,

a really significant portion of polycythemia vera patients will progress to post -PV myelofibrosis.

So that potential for transformation really just underscores that they all belong to a single spectrum of disease.

And the ultimate danger, the end of the line for all of them, is transformation into acute myeloid leukemia.

AML.

That's always a big fear.

And the reason for this shared lineage, this slippery slope lies in their core genetic lesions.

We're talking about key acquired mutations in genes that code for tyrosine kinases or proteins that work with them.

These are the master switches for cell growth.

They are.

And every student of hematology needs to know three genes by heart.

First, JAK2, which is Janus -associated kinase II.

Second, C -ALR for cal reticulin.

And third, MPL, which is the receptor for thrombo -poietin.

And if we're talking about the one single dominant driver across this whole spectrum, it has to be the JAK2 V617F mutation.

AML.

Oh, dominant is an understatement.

The JAK2 V617F mutation is found in almost every single polycythemia vera patient.

We're talking 97%.

AML.

97, that's incredible.

AML.

And it's also there in about 60 % of both ET and PMF cases.

So that one finding immediately tells you there's a common unifying pathway here.

AML.

It's amazing that a single point mutation can do all that.

And even in that tiny minority of PV cases that are JAK2 V617F negative, it's still a JAK2 problem, right?

AML.

Almost always.

It's usually a different JAK2 mutation, typically in a region called exon 12.

So no matter how you slice it, for PV, uncontrolled JAK2 activation is the central mechanism.

It is the engine.

AML.

Okay, so let's break that down.

What's the mechanism of that JAK2 activation?

How does it normally work?

AML.

It's a classic molecular story.

Normally, JAK2 is a cytoplasmic tyrosine kinase.

It partners up with growth factor receptors on the cell surface, like the receptor for erythropiatin or EPO.

When EPO binds on the outside of the cell, the two halves of the receptor kind of move closer together.

This lets the JAK2 molecules inside the cell activate each other.

They phosphorylate each other.

AML.

And that's the on switch.

AML.

That's the on switch.

And it triggers this huge cascade of downstream proteins, like the stat proteins, which then travel into the nucleus and deliver the message,

proliferate and survive.

So it's a beautifully regulated system.

It needs that external signal, the growth factor, to turn the key.

AML.

Exactly.

The key is that external signal.

The V617F mutation, however, just hotwires the whole system.

The mutation is in a very specific part of the JAK2 protein called the pseudokinase domain.

This part normally acts as an internal break, a negative regulator.

The V617F mutation changes one amino acid, and that's enough to stop that break from working properly.

AML.

So it's like a gate that's permanently stuck open.

AML.

That's a great way to put it.

It allows the JAK protein to become constitutively activated.

It's always on.

Even when there's no growth factor, no EPO bound to the outside, the signaling pathway is just permanently firing.

AML.

Giving that one cell line a massive unregulated advantage.

AML.

Proliferative and survival, yes.

AML.

So wait, this explains that classic finding in PV.

The body isn't overproducing erythropoietin.

The cell is just acting like it's flooded with it.

And that's why the EPO level in the blood is characteristically low.

The body is screaming, stop making red cells by shutting down EPO production, but the mutated cell can't hear it.

It's deaf to the signal.

AML.

That's a crucial distinction.

Okay, so if the same JAK2 mutation is in PV, ET, and PMF, why does one person get too many red cells and another person gets too many platelets?

AML.

Right.

This brings us to the concept of allele dosage.

AML.

The quantity of the mutation matters.

It matters a lot.

The dosage of the mutant JAK2 allele often dictates what the disease looks like.

In Positethaemia vera, the allele burden is typically much, much higher than in essential thrombocytemia.

In fact, in PV, you can get a secondary event, a mitotic recombination, that leads to a homozygous JAK2 mutation state.

AML.

Meaning both copies of the gene are mutated.

Both copies.

And when a patient is homozygous, the on signal is so overwhelmingly powerful that it just drives red cell production above everything else.

That's what gives you PV.

AML.

So heterozygous -1 mutated copy usually points more towards ET or PMF, but homozygous is a huge signpost for PV.

Wow, that's a perfect example of genotype influencing phenotype.

AML.

It is.

Now, that covers the JAK2 positive world.

But what about the 40 % or so of ET and PMF cases that are JAK2 negative?

What's driving them?

AML.

Which brings us to our other two key players, CALR and MPL.

Exactly.

If a patient with suspected ET or PMF is JAK2 negative, the next test you run is for CALR.

You'll find a CALR mutation in about three quarters of JAK2 negative ET patients.

AML.

And what does CLR normally do?

How is its mutation different from JAK2?

AML.

Well, CLR is normally a chaperone protein.

It lives in the endoplasmic reticulum, helps fold other proteins.

The mutations we see in MPNs are usually frameshift mutations.

AML.

So they change the entire end of the protein.

They create a brand new abnormal C -terminus on the protein.

And this is a critical distinction from JAK.

AML.

Because unlike JAK2, which is activated inside the cell, the mutated CLR protein works from the outside.

AML.

Precisely.

The mutated CLR protein actually gets secreted from the cell.

And once it's outside, it binds abnormally and persistently to the thrombo -poetin receptor, which is MPL on the cell surface.

AML.

Ah, so it's hijacking the receptor from the outside.

AML.

It is.

It's an external hijacking rather than an internal short circuit.

But the result is the same.

Constitutive activation of the JAK -STAT pathway, leading to proliferation, especially of megakaryocytes.

AML.

That makes it much clearer.

And finally, MPL itself, the receptor, can be directly mutated.

AML.

Yes.

You can get constitutively activating mutations directly in the MPL gene.

It's less common.

Maybe 5 % of ET and 10 % of PMF.

But when you add them all up, JK2, CLR, and MPL, you've accounted for almost every case of PV and the vast majority, maybe 90 % of ET and PMF.

It's a stunningly simple picture in a way, but the story can't end with just the primary driver.

For prognosis, you have to talk about cooperating mutations.

PML.

Absolutely.

This is where it gets more complex, but so much more clinically useful.

In 10 -20 % of patients, and more as they get older, we find additional mutations.

These are often in genes that control epigenetic regulation.

Genes with names like TT2, ASXL1, DNMT3A, they occur alongside the main driver, and they fundamentally change the disease's trajectory.

AML.

So they're like molecular warnings of what's to come.

PML.

They are powerful predictors.

If you have one of these, it's associated with much faster disease progression, quicker transformation to myelofibrosis, and just lower overall survival.

But the real alarm bells go off when clinicians find mutations in TP53 and RUNX1.

AML.

Why are those two so dangerous?

PML.

Because they are highly, highly associated with transformation to acute myeloid leukemia.

If a patient has a CLR driver, which we think of as good, but also has a cooperating RUNX1 mutation, well, their prognosis is now defined by the secondary mutation, not the primary one.

AML.

Which is why just testing for JAK2 isn't enough anymore.

You need the full panel.

PML.

You need the full panel to accurately risk stratify the patient.

AML.

And just quickly, what about hereditary risk?

PML.

It's interesting.

The incidence of MPN is about five times higher in close relatives.

And this is linked to a common germline polymorphism in JAK2 called JAK2 461.

AML.

So it's not the cancer mutation itself, but it sets the stage.

PML.

It sets the stage.

It creates a genetic background that makes the stem cells a bit more susceptible to picking up that critical somatic driver mutation later in life.

It sort of lowers the barrier to entry.

AML.

A perfect foundation.

We have the Now let's apply that to the first of the big three, polycythemia and specifically polycythemia vera.

PML.

Okay.

So to talk about PV, we first need a really precise definition of polycythemia itself.

Clinically, it's just an increase in hemoglobin concentration above the normal limit for that patient's age and sex.

But the real work is classifying why the AGP is high.

AML.

Right.

So first step is classifying by volume.

Is this real or not?

PML.

Exactly.

We have to differentiate between absolute erythrocytosis and what we call relative polycythemia.

Absolute means the total red cell mass in the body is genuinely raised, more than 125 % of predicted.

And a key clinical shortcut here,

if a patient's hematocrit, their HCT is above 0 .60, you can be certain it's an absolute polycythemia.

AML.

The source material mentions the old radio dilution methods using radioactive chromium to prove this.

PML.

Yeah.

A fascinating historical point.

Those used to be mandatory, but now with molecular testing for JAK2, we rarely need them.

But the concept is still vital.

Is the red cell mass truly high?

AML.

Because the alternative is relative or pseudo polycythemia.

PML.

Which is just a concentration artifact.

The red cell volume is normal, but the plasma volume is low, so the blood looks spicker.

You see this with diuretics, dehydration, but also chronically with heavy smoking, obesity, high alcohol intake.

AML.

And the key point is you do not perform phlebotomy on these patients.

PML.

Absolutely not.

They don't have too many red cells.

They need their fluid balance or lifestyle fixed.

AML.

Okay.

So once we confirm it's absolute, the next step is cause.

Primary versus secondary.

PML.

Right.

Secondary is reactive, driven by erythropoietin.

This can be from central hypoxia.

The body thinks it needs more oxygen carriers.

So chronic lung disease, high altitude, severe sleep apnea, or pathological epoproduction where tumor is making it inappropriately.

The classic ones are renal cell cancer and hepatocellular carcinoma.

In all these secondary causes, the body's EPO level will be high.

AML.

Which finally brings us to primary polysathemia vera.

PML.

The acquired clonal malignancy of a stem cell, driven, as we said, almost always by a JAK2 mutation.

And while the red cell overproduction is a hallmark, it's so important to remember PV is a panmyelosis.

You often get too many granulocytes and platelets too.

AML.

Let's talk about the classic clinical picture.

This is a disease of older people, and the symptoms are driven by three things.

Hyperviscosity, hypervolemia, and hypermetabolism.

PML.

And that triad gives you so many symptoms.

Headaches, dizziness, blurred vision, the hypermetabolism causes weight loss and these awful night sweats.

But the most characteristic symptom, the one that's almost pathognomonic, is generalized pruritus.

AML.

The itching.

PML.

This intense itching, which is classically triggered or made much, much worse by hot water, like after a shower.

AML.

Why does that happen?

PML.

The theory is that due to massive histamine or prostaglandin release from the increased number of basophils and mass cells that are part of that same clone,

the heat is the trigger.

AML.

And what does the patient look like on examination?

PML.

They can have a very classic plethoric appearance,

a ruddy cyanosis, the face looks flushed, almost purple -red, you see conjunctival suffusion, bloodshot eyes, and about 75 % of patients will have an enlarged spleen.

AML.

And the complications can be severe.

Thrombosis?

PML.

Both arterial, like a heart attack or stroke, and venous, like a DVT.

And paradoxically, also hemorrhage, because the platelets don't function properly.

And gout from the high cell turnover and uric acid production.

AML.

So how does this all fit into the official WHO diagnostic criteria?

PML.

Okay, so you need the lab findings, obviously.

High hemoglobin and hematocrit.

But the three major criteria are key.

One, the high HDT.

Two, a bone marrow biopsy showing hypercellularity growth in all three cell lines, panmyelosis.

And three, the presence of that JAK2 mutation.

AML.

And the single most crucial biochemical finding that separates PV from everything else.

PML.

A subnormal serum erythropoietin level.

It's the absolute hallmark of a primary polysathemia.

As we said, the clone is autonomous, so the body slams the brakes on EPO production.

In PV, EPO is low.

In secondary polysathemia, EPO is high.

AML.

The diagnostic approach is laid out in stages, which is really helpful.

PML.

Yes, the three -stage approach is how clinicians think.

Stage one is your initial screen, FBC, JAK2 test, EPO level.

If JAK2 is negative, but the EPO is still low or there's no obvious secondary cause, you move to stage two.

AML.

Which includes the bone marrow biopsy.

PML.

The bone marrow biopsy and an abdominal ultrasound.

The biopsy is critical, not just for diagnosis, but to look for any early myofibrothus, which tells you the disease might progress faster.

AML.

And stage three is for the really rare stuff.

PML.

Highly specialized testing, yeah.

Raric and general defects, things like that.

AML.

Okay, management.

The goal is to get that viscosity down and reduce cardiovascular risk.

PML.

The number one goal is strict control of the hematocrit.

You have to keep it below 0 .45.

And the fastest way to do that is venus section, therapeutic phlebotomy.

AML.

Just taking blood out.

Simple, but effective.

PML.

Very effective.

Especially for rapid control at the beginning.

It's often the main therapy for younger, low -risk patients.

You physically remove the excess red cells, and as a bonus, you induce iron deficiency, which naturally limits the marrow's ability to make more.

AML.

But the downside is it doesn't control the platelet count.

PML.

Correct.

And sometimes that induced iron deficiency can even make the platelet count climb higher, which is why for high -risk patients over 60 or with a prior thrombosis, we move to cytoreduction.

AML.

And the workhorse drug there is hydroxycarbamide.

PML.

Or hydroxyurea.

It's a key cytoreductive agent.

It works by interfering with DNA synthesis, so it suppresses the overactive bone marrow.

It's great for high -risk patients or those with really high platelet counts.

It controls all three cell lines.

AML.

But it has long -term side effects to watch for.

PML.

Absolutely.

You have to monitor the blood counts closely to avoid oversuppression, and after long -term use, you can see skin toxicity ulcers, hyperpigmentation.

And because it's teratogenic, it's not the first choice for younger women.

AML.

Which brings us to the targeted therapies, the JAK inhibitors.

PML.

Ruxolitinib is the main one here.

It's a potent inhibitor of JAK2.

Right now, it's for PV patients who don't respond to or can't tolerate hydroxycarbamide, or for those with really severe symptoms, like a huge spleen or debilitating night sweats.

AML.

And it works well.

PML.

It's remarkably effective at shrinking the spleen and improving those constitutional symptoms.

Really improves quality of life.

AML.

Are there any other options?

PML.

Yes.

Injectable alpha interferon is another.

It's less convenient, but it's often preferred for younger patients, especially those planning a pregnancy, because it has a better long -term safety profile.

And of course, low -dose aspirin for almost everybody to prevent clots.

AML.

And the prognosis for PV?

PML.

Median survival is pretty good, often over 10 years.

But the long -term risks are thrombosis, hemorrhage, and progression.

About 30 % of patients will progress to post -PV malifibrosis, and around 5 % will transform to AML.

AML.

A very comprehensive look at PV.

Let's pivot now to the second of the big three, where the focus shifts squarely to platelets.

Essential thrombocytemia.

OK.

Essential thrombocytemia, or ET.

This is defined by a sustained platelet count over 450 times 10 to the 9 per liter.

It's from a clonal megakaryocyte proliferation, but the key is what it isn't.

AML.

The exclusion criteria.

PML.

Exactly.

The patient has to have a normal hematocrit, so it's not PV.

No evidence of primary malifibrosis.

And definitely no BCRABL1 fusion gene, which would mean it's chronic myeloid leukemia.

AML.

That list is so important.

It means the very first step in thinking about ET is ruling out reactive thrombocytosis.

PML.

Absolutely.

Reactive causes of high platelets are incredibly common.

Chronic iron deficiency, hemorrhage, post -plenectomy, chronic infections, underlying cancer.

The list is long.

You can only make a positive diagnosis of ET once all of that is excluded.

AML.

And now we have the molecular tests to give us that positive confirmation.

What are the WHO diagnostic criteria?

PML.

There are four major criteria.

First, the sustained high platelet count.

Second, the crucial bone marrow findings.

You see proliferation that is predominantly

megakaryocytes.

These cells are enlarged, mature, with hyperlopulated nuclei.

AML.

And not much hybrosis at this stage.

PML.

Right.

Third, you've excluded all the other myeloid cancers.

And fourth, the big one.

You have to demonstrate one of the pathogenetic mutations, JK2, C -ALR, or MPL.

AML.

So molecular testing is now basically mandatory.

PML.

Plans are care.

Clinically, most ET is found by accident on a routine blood test.

But when patients do have symptoms, it's all about thrombosis and hemorrhage.

AML.

And this is that paradox again.

Why does having too many platelets cause both clotting and bleeding?

PML.

It's a great question.

The thrombosis risk is from the sheer number and activation state of the platelets, especially in the JK2 mutated patients.

But the hemorrhage risk comes from the fact that the platelets are dysfunctional.

When the platelet count gets extremely high, say over 1500, they essentially consume a critical clotting protein called von Willebrand factor from the plasma.

This leads to an acquired von Willebrand syndrome.

So despite the massive numbers, the platelets can't stick together properly and you get bleeding.

AML.

Fascinating.

And what about that classic microvascular symptom?

PML.

Erythermalalgia.

A real telltale sign.

It's a burning pain in the hands or feet, often with redness.

And it is classically, dramatically relieved by low dose aspirin.

AML.

And on the blood film, what are the key

You see a sea of platelets, but it's not just the quantity, it's the quality.

You'll see abnormally large platelets, sometimes even fragments of megakaryocytes that have broken off and are circulating.

AML.

Let's go back to the genetics.

Because in ET, the difference between a JK2 driver and a C -A -L -R driver is like night and day.

PML.

It's a critical distinction.

They are almost two different diseases prognostically.

JK2 mutated ET tends to affect older patients, they often have slightly higher hemoglobin and

they carry a much higher intrinsic thrombosis risk.

AML.

And that thrombosis risk is linked to something called nets.

PML.

Yes, neutrophil extracellular traps.

These are webs of chromatin that neutrophils release.

In JK2 MPNs, they're released excessively and they provide this highly prothrombotic scaffold that promotes clotting.

And crucially, JK2 ET can transform to PV or myelofibrosis.

AML.

While the C -A -L -R cases are almost the same, they have a lower thrombosis risk and often present with extremely high platelet counts.

And the key prognostic point,

C -A -L -R patients do not transform to PV.

Their overall prognosis is markedly better, with survival over 25 years.

PML.

This molecular fingerprint makes risk stratification absolutely essential.

AML.

How do you approach treatment?

PML.

It's all about reducing vascular risk.

Baseline therapy for almost everyone is low -dose aspirin.

Then for cytoreduction, we stratify patients into high and low -risk.

AML.

And who is high -risk?

PML.

High -risk patients are those over 60, anyone with a prior history of thrombosis or anyone with an extremely high platelet count over 1500.

This group needs cytoreductive drugs, and hydroxycarbamide is still the standard first choice.

AML.

And low -risk patients?

PML.

Younger than 60, no thrombosis history, moderate platelet counts.

They can often be managed safely with just aspirin and careful monitoring.

AML.

What if hydroxycarbamide isn't an option?

PML.

The main second -line drug is anagrolide, which selectively targets megakaryocyte maturation, but it can have cardiovascular side effects.

Pidulated alpha interferon is also very effective and is the preferred choice for younger patients or those planning a pregnancy.

AML.

Overall, the course of ET seems much more indolent than PV.

PML.

It often is.

The disease can be stationary for 10, 20 years or more.

And the risk of transformation to AML is the lowest of the big three, typically less than 5%.

AML.

Which brings us to our third and most aggressive of the classic MPNs, primary myelofibrosis.

PML.

Yes, primary myelofibrosis, or PMF.

This is really the end -stage pathology of the MPN spectrum.

Its hallmark is a progressive, generalized, and this is a critical word, reactive fibrosis of the bone marrow.

AML.

Reactive is the key.

So the fibroblasts, the cells laying down the scar tissue, they aren't the primary problem.

PML.

They are not.

The fibrosis is a secondary reaction.

The real bad actors are the abnormal hyperplastic mega -karyocytes from the malignant clone.

AML.

Okay.

PML.

They secrete these powerful pro -fibrotic cytokines, platelet -derived growth factor, TGF -beta.

And those cytokines are what stimulate the normal fibroblasts to just churn out excessive fibrous tissue, this dense reticulin and collagen network.

AML.

And if the bone marrow, the body's factory, gets scarred over, where does blood production move to?

It shifts to the liver and the spleen.

This is called extramedullary hemopoiesis.

And because the spleen is now trying to be a bone marrow, it enlarges rapidly and dramatically, leading to the massive splenomegaly that characterizes advanced PMF.

PML.

That's the late -stage picture.

But the source talks about an important early stage, the pre -fibrotic stage.

AML.

This is clinically vital because it can be easily missed.

In this early phase, the marrow is hypercellular.

It's packed with those atypical mega -karyocytes, but there's very little actual fibrosis yet.

These patients look a lot like they have essential thrombocytemia.

AML.

So recognizing this early stage depends entirely on a good bone marrow biopsy and a pathologist who recognizes the cell shapes, not just the scarring.

PML.

Precisely.

And in terms of genetics, PMF is the most diverse.

About 55 % are JAK2 positive, 25 % C -ALR, 10 % MPL.

And we see prognostic differences here, too.

C -ALR mutated patients tend to live longer, while the triple negative patients have the short of survival.

AML.

What are the classic clinical features of established PMF?

PML.

It's a debilitating disease.

The dominant symptoms come from anemia as the marrow fails, and from that massive splenomegaly, which causes abdominal pain and early satiety, you know, feeling full after just a few bites of food.

AML.

And the hypermetabolic symptoms are common here, too?

PML.

Very common.

Significant weight loss, fever, drenching night sweats.

AML.

And in the peripheral blood, what are the telltale signs?

PML.

Anemia is almost universal, but the blood film is often diagnostic.

You look for the leukorethroblastic change in mature white cells and red cells leaking out of the disrupted marrow, but the most characteristic sign of all is the teardrop poikilocytes.

AML.

Teardrop red cells.

PML.

Red cells that have been physically distorted into a teardrop shape as they're squeezed out of that scarred, fibrotic marrow.

AML.

And getting that diagnosis requires a bone marrow biopsy, which can be tricky.

PML.

Yes, the infamous dry tap.

Because the marrow is so fibrotic, you often can't asquerate any liquid marrow.

So the trephine biopsy, the core of bone, is absolutely essential to see the fibrosis.

AML.

Now, PMF has the highest risk of transforming to AML.

How high is that, and what predicts it?

PML.

It's significant, 10 to 20%.

The risk is predicted by specific chromosome abnormalities, like loss of parts of chromosomes 5 or 7, and by those high -risk additional mutations we talked about, especially TP53 and RUNX1.

AML.

Given that high risk, you need a way to systematically assess a patient's prognosis.

For that, we use the Dynamic International Prognostic Scoring System, or DIPSS.

It uses five key variables to calculate a risk score.

AML.

Walk us through the five DIPSS factors.

PML.

You get one point for each of these, age over 65, hemoglobin less than 10, indicating marrow failure, a high white blood cell count over 25, the presence of constitutional symptoms, fever, night sweats, weight loss,

and finally, circulating blasts greater than 1%, which is a sign of impending leukemic transformation.

AML.

And how does that score translate into a prognosis?

PML.

It creates four risk groups that strongly predict survival.

A low -risk patient with zero points has a median survival over 15 years.

But a high -risk patient with 4 to 6 points has a median survival of only about 16 months.

It tells you how aggressive you need to be with therapy.

AML.

So what does treatment for PMF look like?

PML.

For many, it's about symptom management.

Red cell transfusions for anemia,

allopurinol for high uric acid.

But the drug that has truly revolutionized management is ruxolitinib.

AML.

The JAK2 inhibitor again.

Why is it so effective here?

PML.

Because even the CALR and MPL cases ultimately funnel through that jackstab pathway.

So ruxolitinib hits the core engine.

It's incredibly effective at shrinking the spleen and controlling those awful constitutional symptoms.

And importantly, it's been shown to improve overall survival in higher -risk patients.

AML.

What about physically removing the mass of spleen?

PML.

Splenectomy is a last resort.

It's for patients with intractable pain or severe cytopenias from the spleen, sequestering all their blood cells.

But it's a high -risk operation with significant morbidity.

AML.

And is there any chance for a cure?

PML.

The only curative option is an allogeneic stem cell transplant.

But given the age and frailty of most PMF patients, it's only a realistic option for a small fraction of younger, fitter individuals.

AML.

It sounds like molecular risk assessment is more critical here than in any of the others.

PML.

Without a doubt.

Median survival is only three to five years overall.

You have to treat the molecular risk, not just the blood counts.

AML.

Okay, we've covered the big three.

Let's briefly touch on the other rare MPNs, which are fascinating in their own right.

PML.

The first one is mastocytosis,

a clonal proliferation of mast cells.

These cells build up in the bone marrow and, very characteristically, the skin.

AML.

The skin sign is urticaria pigmentosa, those reddish -brown spots.

PML.

Exactly.

But the true MPN is systemic mastocytosis, where it's in the bone marrow and can be very aggressive.

The genetic driver here is very specific.

Over 90 % of cases have a mutation in the Kitchad gene, another tyrosine kinase.

AML.

The D816V mutation.

PML.

The D816V mutation.

And because it's a kinase, it's targetable.

The symptoms come from both the cells -infiltrating organs and the massive release of mediators like histamine.

AML.

And the treatment is targeted therapy.

PML.

Yes.

This is a huge success story.

Tyrosine kinase inhibitors like mitosorin are highly active against that mutated kid receptor.

AML.

Next up, chronic neutrophilic leukemia.

PML.

This is a persistently high white count of mature neutrophils.

The key genetic finding is that most patients have activating mutations in the CSF3R gene, another receptor that signals through a kinase pathway.

So again, kinase inhibitors are showing promise.

AML.

And finally, chronic eosinophilic leukemia.

This is a clonal persistent high eosinosil count that causes severe organ damage, especially to the heart.

PML.

And this one has a very specific, highly targetable driver.

AML.

It does.

It's a brilliant example.

About half of CEL cases are driven by a specific fusion gene,

FIP1L1 -PDGFRA.

And if a patient has that fusion, they have an excellent, often curative response to low -dose imatinib, a TKI.

It's just remarkable how the molecular test dictates the entire treatment pathway now.

PML.

It's the core of modern hematology.

AML.

That covers the full spectrum.

Let's just zoom out for a final recap of the big picture here.

PML.

Right.

So the main conceptual takeaway is this.

PV, ET, and PMF are not separate diseases.

They are deeply interrelated clonal malignancies of a single hematopoietic stem cell.

AML.

And they're unified at the molecular level by those three driver mutations, JK2, CALR, and MPL, which all do the same thing.

They create a constitutively active proliferative signal.

PML.

And the clinical differences we see.

Too many red cells, too many platelets.

It just comes down to which cell lineage happens to dominate, which is often dictated by the allele dosage of that driver mutation.

AML.

And that molecular understanding has completely changed clinical practice.

PML.

Completely.

We now rely on genetic testing to identify the mutation, and then prognostic scoring systems like DIPSS to risk stratify patients.

And that tells us who needs simple venous action and who needs aggressive therapy with JK inhibitors like Ruxolinib.

We've moved from just chasing blood counts to treating the molecular root of the disease.

AML.

So we've focused heavily on the primary drivers, the ignition switch, but what's the final thought for the listener?

Where is this all heading?

PML.

Well, this raises the most important question for the future.

While JK2, CALR, and MPL are the engines, we can't forget those secondary epigenetic mutations like TE2 and ASXL1.

They aren't the primary cause, but their presence fundamentally rewrites the prognosis.

They are the molecular harbingers of progression to myelofibrosis or AML.

They're the real timer on the disease.

So the next great challenge isn't just controlling the high counts, it's developing therapies that can target those secondary risk mutations to prevent leukemic transformation entirely.

That's the frontier.

AML.

practice.

Thank you for guiding us through this incredibly detailed deep dive.

PML.

My pleasure.

AML.

And thank you, the listener, for joining us on the deep dive.

We'll catch you next time.